GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Synergy Pharmaceuticals Inc (FRA:S90) » Definitions » EV-to-FCF

Synergy Pharmaceuticals (FRA:S90) EV-to-FCF : -0.64 (As of May. 21, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Synergy Pharmaceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Synergy Pharmaceuticals's Enterprise Value is €65.50 Mil. Synergy Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2018 was €-102.70 Mil. Therefore, Synergy Pharmaceuticals's EV-to-FCF for today is -0.64.

The historical rank and industry rank for Synergy Pharmaceuticals's EV-to-FCF or its related term are showing as below:

FRA:S90's EV-to-FCF is not ranked *
in the Drug Manufacturers industry.
Industry Median: 25.045
* Ranked among companies with meaningful EV-to-FCF only.

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-21), Synergy Pharmaceuticals's stock price is €0.00. Synergy Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2018 was €-0.480. Therefore, Synergy Pharmaceuticals's PE Ratio for today is At Loss.


Synergy Pharmaceuticals EV-to-FCF Historical Data

The historical data trend for Synergy Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synergy Pharmaceuticals EV-to-FCF Chart

Synergy Pharmaceuticals Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.30 -3.24 -6.70 -8.68 -2.46

Synergy Pharmaceuticals Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Synergy Pharmaceuticals's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Synergy Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Synergy Pharmaceuticals's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Synergy Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Synergy Pharmaceuticals's EV-to-FCF falls into.



Synergy Pharmaceuticals EV-to-FCF Calculation

Synergy Pharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=65.504/-102.702
=-0.64

Synergy Pharmaceuticals's current Enterprise Value is €65.50 Mil.
Synergy Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was €-102.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Synergy Pharmaceuticals  (FRA:S90) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Synergy Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.00/-0.480
=At Loss

Synergy Pharmaceuticals's share price for today is €0.00.
Synergy Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.480.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Synergy Pharmaceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Synergy Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Synergy Pharmaceuticals (FRA:S90) Business Description

Traded in Other Exchanges
N/A
Address
420 Lexington Avenue, Suite 2012, New York, NY, USA, 10170
Synergy Pharmaceuticals Inc functions in the healthcare sector based in the United States. It focusses on developing therapies to combat gastrointestinal diseases. The company's basic ingredient is the uroguanylin analog, which it employs in its products candidates such as plecanatide and dolcanatide. Plecanatide is a once-daily tablet, which addresses chronic idiopathic constipation and the irritable bowel syndrome. Dolcanatide is meant to cure inflammatory bowel disease by aiding the process of digestive breakdown.

Synergy Pharmaceuticals (FRA:S90) Headlines

No Headlines